Europe preventive vaccines market accounted for $10.64 billion in 2020 and will grow by 10.72% annually over 2020-2026 owing to the increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 61 tables and 52 figures, this 140-page report “Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire Europe preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases
Based on Administration, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
Based on Patient, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 28
2.4 Emerging Opportunities and Market Trends 31
2.5 Porter’s Fiver Forces Analysis 35
3 Segmentation of Europe Market by Vaccine Type 39
3.1 Market Overview by Vaccine Type 39
3.2 Live/Attenuated Vaccines 41
3.3 Inactivated Vaccines 42
3.4 Subunit Vaccines 43
3.5 Toxoid Vaccines 44
3.6 Conjugate Vaccines 45
3.7 Recombinant Vector Vaccines 46
3.8 Other Vaccines 47
4 Segmentation of Europe Market by Disease 48
4.1 Market Overview by Disease 48
4.2 Vaccines for Pneumococcal Disease 50
4.3 Vaccines for Poliovirus 51
4.4 Vaccines for Hepatitis 52
4.5 Vaccines for Influenza 53
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 54
4.7 Vaccines for Varicella 55
4.8 Vaccines for Human Papilloma Virus 56
4.9 Vaccines for COVID-19 57
4.10 Vaccines for Other Diseases 60
5 Segmentation of Europe Market by Administration 61
5.1 Market Overview by Administration 61
5.2 Intramuscular Route 63
5.3 Subcutaneous Route 64
5.4 Oral Route 65
5.5 Intravenous Injection 66
5.6 Other Administration Routes 67
6 Segmentation of Europe Market by Patient 68
6.1 Market Overview by Patient 68
6.2 Pediatric Vaccines 70
6.3 Adult Vaccines 72
7 European Market 2020-2026 by Country 74
7.1 Overview of European Market 74
7.2 UK 77
7.3 France 80
7.4 Germany 83
7.5 Spain 86
7.6 Italy 89
7.7 Russia 92
7.8 Rest of European Market 95
8 Competitive Landscape 97
8.1 Overview of Key Vendors 97
8.2 New Product Launch, Partnership, Investment, and M&A 100
8.3 Company Profiles 101
AstraZeneca plc 101
Bavarian Nordic A/S 104
China National Biotec Group Company Ltd. 107
CSL Ltd. 109
Daiichi Sankyo Co. Ltd 111
Emergent BioSolutions Inc. 113
GlaxoSmithKline plc 115
Johnson & Johnson 119
Merck & Co. 121
Moderna Inc. 123
Novavax, Inc. 124
Pfizer Inc. 126
Sanofi SA 130
Takeda Pharmaceutical Co. Ltd. 132
9 Investing in Europe Market: Risk Assessment and Management 134
9.1 Risk Evaluation of Europe Market 134
9.2 Critical Success Factors (CSFs) 137
Related Reports and Products 140
Table 1. Snapshot of Europe Preventive Vaccines Market in Balanced Perspective, 2020-2026 17
Table 2. Growth Rate of World GDP, 2020-2022 22
Table 3. Main Product Trends and Market Opportunities in Europe Preventive Vaccines Market 31
Table 4. Europe Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 39
Table 5. Europe Preventive Vaccines Market by Disease, 2016-2026, $ mn 48
Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021 58
Table 7. Europe Preventive Vaccines Market by Administration, 2016-2026, $ mn 61
Table 8. Europe Preventive Vaccines Market by Patient, 2016-2026, $ mn 68
Table 9. Europe Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 71
Table 10. Europe Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 73
Table 11. Europe Preventive Vaccines Market by Country, 2016-2026, $ mn 76
Table 12. UK Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 78
Table 13. UK Preventive Vaccines Market by Disease, 2016-2026, $ mn 78
Table 14. UK Preventive Vaccines Market by Administration, 2016-2026, $ mn 79
Table 15. France Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 81
Table 16. France Preventive Vaccines Market by Disease, 2016-2026, $ mn 81
Table 17. France Preventive Vaccines Market by Administration, 2016-2026, $ mn 82
Table 18. Germany Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 84
Table 19. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 84
Table 20. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 85
Table 21. Spain Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 87
Table 22. Spain Preventive Vaccines Market by Disease, 2016-2026, $ mn 87
Table 23. Spain Preventive Vaccines Market by Administration, 2016-2026, $ mn 88
Table 24. Italy Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 90
Table 25. Italy Preventive Vaccines Market by Disease, 2016-2026, $ mn 90
Table 26. Italy Preventive Vaccines Market by Administration, 2016-2026, $ mn 91
Table 27. Russia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 93
Table 28. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 93
Table 29. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 94
Table 30. Preventive Vaccines Market in Rest of Europe by Country, 2016-2026, $ mn 96
Table 31. AstraZeneca plc: Company Snapshot 101
Table 32. AstraZeneca plc: Revenue, 2018-2020, $ bn 102
Table 33. Bavarian Nordic A/S: Company Snapshot 104
Table 34. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 105
Table 35. China National Biotec Group Company Ltd.: Company Snapshot 107
Table 36. CSL Ltd.: Company Snapshot 109
Table 37. Daiichi Sankyo Co. Ltd.: Company Snapshot 111
Table 38. Emergent BioSolutions Inc.: Company Snapshot 113
Table 39. GlaxoSmithKline: Company Snapshot 115
Table 40. GlaxoSmithKline: Business Segmentation 116
Table 41. GlaxoSmithKline: Product Portfolio 117
Table 42. GlaxoSmithKline: Revenue, 2018-2020, $ bn 118
Table 43. GlaxoSmithKline: Recent Developments 118
Table 44. Johnson & Johnson: Company Snapshot 119
Table 45. Johnson & Johnson: Business Segments 120
Table 46. Merck & Co., Inc.: Company Snapshot 121
Table 47. Merck & Co., Inc.: Business Segmentation 121
Table 48. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 122
Table 49. Moderna Inc.: Company Snapshot 123
Table 50. Novavax, Inc.: Company Snapshot 124
Table 51. Pfizer Inc.: Company Snapshot 126
Table 52. Pfizer Inc.: Business Segmentation 127
Table 53. Pfizer Inc.: Product Portfolio 128
Table 54. Pfizer Inc.: Revenue, 2018-2020, $ bn 129
Table 55. Pfizer Inc.: Recent Developments 129
Table 56. Sanofi: Company Snapshot 130
Table 57. Sanofi: Business Segmentation 130
Table 58. Sanofi: Revenue, 2018-2020, $ bn 131
Table 59. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 132
Table 60. Risk Evaluation for Investing in Europe Market, 2020-2026 135
Table 61. Critical Success Factors and Key Takeaways 138
